Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

799.56 +2.64 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
The Latest Analyst Ratings for argenx
 
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
What 20 Analyst Ratings Have To Say About argenx
 
Via Benzinga
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases. 
Via Investor's Business Daily
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
These stocks could lead if the market rallies. 
Via Investor's Business Daily
Topics Stocks
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
 
Via Benzinga
Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market
Arista Networks and Dutch biotech Argenx lead this weekend's watch list. 
Via Investor's Business Daily
Topics Artificial Intelligence
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Is Argenx Stock a Buy Now?
Good news keeps rolling in for the biotech. 
Via The Motley Fool
Earnings Outlook For argenx
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
 
Via Benzinga
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week. 
Via Investor's Business Daily
argenx Unusual Options Activity
 
Via Benzinga
Why Shares of Argenx Jumped This Week
The company's lead therapy showed progress in treating an autoimmune disorder. 
Via The Motley Fool
The Latest Analyst Ratings for argenx
 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
 
Via Benzinga
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
Why Argenx Stock Is on Fire Today
A major clinical win is boosting the drugmaker's shares today. 
Via The Motley Fool
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.